Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ciprofloxacin

FDA-approved product (injectable, injection), marketed as Cipro, Cipro In Dextrose 5% In Plastic Container, Cipro In Sodium Chloride 0.9% In Plastic Container and 8 more.

Registered studies
50+
Lab records
592
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ciprofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Cystitis
  • Eye infection
  • Gonorrhea
  • Infection
  • Otitis externa
  • Prostatitis
  • Pyelonephritis
  • Sinusitis
  • Typhoid fever
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA02; WHO ATC S01AE03

Repurposing investigation

Ciprofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 118 of 130 lab records
  • E. coli: measured active in 134 of 137 lab records
  • K. pneumoniae: measured active in 264 of 294 lab records
  • M. tuberculosis: measured active in 29 of 31 lab records
Open Ciprofloxacin in ChEMBL Registered studies below
Show the latest 150 of 592 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ciprofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Non-operative Treatment of Acute Non-perforated Appendicitis

    NCT04030741 · start 2018-09-01

    Registered record
    Registry ID
    NCT04030741
    Conditions
    Acute Appendicitis
    Interventions
    Meronem and flagyl; Appendectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2020-12-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionMeronem and flagyl; Appendectomy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

    NCT03354598 · start 2018-08-01

    Registered record
    Registry ID
    NCT03354598
    Conditions
    Uncomplicated Urinary Tract Infections
    Interventions
    Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-01
    Completion
    2020-01-20
    Enrolment
    1,671

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Urinary Tract Infections
    InterventionSulopenem-Etzadroxil/Probenecid; Ciprofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Fluoroquinolone Associated Disability

    NCT03535558 · start 2018-05-17

    Registered record
    Registry ID
    NCT03535558
    Conditions
    Bronchitis; Sinusitis; Urinary Tract Infections
    Interventions
    Fluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2018-12-31
    Enrolment
    239,306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Sinusitis; Urinary Tract Infections
    InterventionFluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    PhaseNot recorded
    Registry statusCompleted

  • S. Aureus Decolonization in HPN Patients.

    NCT03173053 · start 2018-02-08

    Registered record
    Registry ID
    NCT03173053
    Conditions
    Staphylococcus Aureus; Motility Disorder
    Interventions
    Doxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin; Clarithromycin; Ciprofloxacin; Fusidic Acid; Rifampin; Chlorhexidine; Mupirocin; Betadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2021-10-14
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; Motility Disorder
    InterventionDoxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin +7 more
    PhaseNot applicable
    Registry statusTerminated

  • Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

    NCT03519516 · start 2018-01-25

    Registered record
    Registry ID
    NCT03519516
    Conditions
    Conjunctivitis; Conjunctivitis, Bacterial
    Interventions
    PRO-174; Sophixín Ofteno®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2018-06-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis; Conjunctivitis, Bacterial
    InterventionPRO-174; Sophixín Ofteno®
    PhasePhase 1
    Registry statusCompleted

  • The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon

    NCT04003181 · start 2017-09-28

    Registered record
    Registry ID
    NCT04003181
    Conditions
    Colon Adenocarcinoma; Diarrhea
    Interventions
    Antibiotics; Bile Acid Binder
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-09-28
    Completion
    2021-05-26
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Adenocarcinoma; Diarrhea
    InterventionAntibiotics; Bile Acid Binder
    PhaseNot applicable
    Registry statusCompleted

  • Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients

    NCT02389036 · start 2017-05-01

    Registered record
    Registry ID
    NCT02389036
    Conditions
    Critical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    Interventions
    SDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2023-04-26
    Enrolment
    20,010

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    InterventionSDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    PhasePhase 3
    Registry statusCompleted

  • Experimental Human Infection With Neisseria Gonorrhoeae

    NCT03840811 · start 2017-04-23

    Registered record
    Registry ID
    NCT03840811
    Conditions
    Gonococcal Infection
    Interventions
    Cefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26; Neisseria gonorrhoeae strain FA7537
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-23
    Completion
    2019-11-25
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonococcal Infection
    InterventionCefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26 +1 more
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy

    NCT03084601 · start 2017-03-01

    Registered record
    Registry ID
    NCT03084601
    Conditions
    Necrotic Pulp; Postoperative Pain
    Interventions
    Calcium Hydroxide, Iodoform, paste; 3-mixtatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-03-01
    Completion
    2018-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNecrotic Pulp; Postoperative Pain
    InterventionCalcium Hydroxide, Iodoform, paste; 3-mixtatin
    PhasePhase 4
    Registry statusCompleted

  • Special Drug Use Investigation of Ciproxan Injection in Pediatrics

    NCT02555059 · start 2016-07-15

    Registered record
    Registry ID
    NCT02555059
    Conditions
    Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
    Interventions
    Cipro (Ciprofloxacin, BAYQ3939)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-07-15
    Completion
    2019-06-13
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
    InterventionCipro (Ciprofloxacin, BAYQ3939)
    PhaseNot recorded
    Registry statusCompleted

  • Non-operative Management for Appendicitis in Children

    NCT02795793 · start 2016-05

    Registered record
    Registry ID
    NCT02795793
    Conditions
    Acute Focal Appendicitis; Appendicitis
    Interventions
    Non-operative management group (NOM); Appendectomy group (Operative management, OM)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-05
    Completion
    2019-12
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Focal Appendicitis; Appendicitis
    InterventionNon-operative management group (NOM); Appendectomy group (Operative management, OM)
    PhaseNot applicable
    Registry statusUnknown

  • Dose Ranging Study of OTO-201 in AOMT

    NCT02719158 · start 2016-02

    Registered record
    Registry ID
    NCT02719158
    Conditions
    Acute Otitis Media; AOMT
    Interventions
    6 mg ciprofloxacin; 12 mg ciprofloxacin; Sham
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-07
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media; AOMT
    Intervention6 mg ciprofloxacin; 12 mg ciprofloxacin; Sham
    PhasePhase 2
    Registry statusCompleted

  • The Effect of Colistin Inhalation on Ventilator Associated Pneumonia

    NCT03622450 · start 2016-01-02

    Registered record
    Registry ID
    NCT03622450
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Colistin; Carbapenem + Aminoglycoside/ Quinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-01-02
    Completion
    2018-01-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionColistin; Carbapenem + Aminoglycoside/ Quinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Antibiotic Prophylaxis With Routine Ureteral Stent Removal

    NCT02944825 · start 2016-01

    Registered record
    Registry ID
    NCT02944825
    Conditions
    Urolithiasis; UTI
    Interventions
    Ciprofloxacin; trimethoprim/sulfamethoxazole; No Intervention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-01
    Completion
    2025-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrolithiasis; UTI
    InterventionCiprofloxacin; trimethoprim/sulfamethoxazole; No Intervention
    PhaseNot applicable
    Registry statusCompleted

  • Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

    NCT02118909 · start 2014-05

    Registered record
    Registry ID
    NCT02118909
    Conditions
    Healthy Volunteers; Non-smokers
    Interventions
    Pracinostat; Itraconazole; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Non-smokers
    InterventionPracinostat; Itraconazole; Ciprofloxacin
    PhasePhase 1
    Registry statusCompleted